Positron emission tomography in lung cancer
详细信息 查看全文
- 作者：Hiroaki Nomori (1)
Yasuomi Ohba (1)
Kentaro Yoshimoto (1)
Hidekatsu Shibata (1)
Kenji Shiraishi (1)
Takeshi Mori (1) - 关键词：Positron emission tomography ; Lung cancer ; Staging ; Prognosis ; Chemoradiotherapy
- 刊名：General Thoracic and Cardiovascular Surgery
- 出版年：2009
- 出版时间：April 2009
- 年：2009
- 卷：57
- 期：4
- 页码：184-191
- 全文大小：299KB
- 参考文献：1. Scott WJ, Schwabe JL, Gupta NC, Dewan NA, Reeb SD, Sugimoto JT, et al. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F] fluorodeoxy-glucose. Ann Thorac Surg 1994;58:698鈥?03.
2. Patz EF, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487鈥?90.
3. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996;37:943鈥?48.
4. Gupta N, Gill H, Graeber G, Bishop H, Hurst J, Stephens T. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest 1998;114:1105鈥?111. CrossRef
5. Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE, et al. Analytical decision model for the cost-effectiveness management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113鈥?125.
6. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914鈥?24. CrossRef
7. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules: potential role in evaluation and management. Chest 1993;104:997鈥?002. CrossRef
8. Higashi, K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar carcinoma. J Nucl Med 1998;39:1016鈥?020.
9. Imdahl A, Jenkner S, Brink I, Nitzsche E, Stoelben E, Moser E, et al. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions. Eur J Cardiothorac Surg 2001;20:324鈥?29. CrossRef
10. Coleman RE. PET in lung cancer. J Nucl Med 1999;40:814鈥?20.
11. McLoud TC. Imaging techniques for diagnosis and staging of lung cancer. Clin Chest Med 2002;23:123鈥?36. CrossRef
12. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075鈥?084.
13. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer 2004;45:19鈥?7. CrossRef
14. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994;35:1771鈥?776.
15. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d -glucose: variations with body weight and a method for correction. Radiology 1993;189:847鈥?50.
16. Kim CK, Gupta NC, Chandramouli B, Alavi A. Standarized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994;35:164鈥?67.
17. Kim CK, Gupta NC. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction. Nucl Med Commun 1996;17:890鈥?94.
18. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med 1993;34:1鈥?.
19. Langen KJ, Braun U, Rota Kops E, Herxog H, Kuwert T, Nebeling B, et al. The influence of plasma glucose levels of fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993;34:355鈥?59.
20. Hamberg LM, Hunter GI, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994;35:1308鈥?312.
21. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998;19:1055鈥?063. CrossRef
22. Menda Y, Bushnell DL, Madsen MT, McLaughlin K, Kahn D, Kernstine KH. Evaluation of various corrections to the standardized uptake value for diagnosis of pulmonary malignancy. Nucl Med Commun 2001;22:1077鈥?081. CrossRef
23. Obrzut S, Pham RH, Vera DR, Badran K, Hoha CK. Comparison of lesion-to-cerebellum uptake ratios and standardized uptake values in the evaluation of lung nodules with 18F-FDG PET. Nucl Med 2007;27:7鈥?3. CrossRef
24. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. Ann Thorac Surg 2005;79:984鈥?88. CrossRef
25. Ohba Y, Nomori H, Shibata H, Kobayashi H, Mori T, Shiraishi S, et al. Evaluation of semiquantitative analyses of F-18 fluorodeoxyglucose uptake on PET scans for the diagnosis of non-small cell lung cancer less than 3 cm in size. Ann Thorac Surg 2009 (in press).
26. Gupta NC, Tamin WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001;120:521鈥?27. CrossRef
27. Gupta NC, Geoffrey M, Graeber GG, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (< 1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest 2000; 117:773鈥?78. CrossRef
28. Graeter TP, Hellwig D, Hoffman K, Ukena D, Kirsch CM, Schafers HJ. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 2003;75:231鈥?36. CrossRef
29. Chin R Jr, Ward R, Keyes JW, Choplin RH, Reed JC, Wallenhaupt S, et al. Mediastinal staging of non-small cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995;152:2090鈥?096.
30. Bury T, Paulus P, Dowlati A, Corhay JL, Weber T, Ghaye B, et al. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 1996;9:2560鈥?564. CrossRef
31. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, et al. Staging non-small cell lung cancer by whole-body positron emission tomography imaging. Ann Thorac Surg 1995;60:1573鈥?582. CrossRef
32. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s: meta-analytic comparison of PET and CT. Radiology 1999;213:530鈥?36.
33. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. J Thorac Cardiovasc Surg 2004;127:1087鈥?092. CrossRef
34. Ebihara A, Nomori H, Watanabe K, Ohtsuka T, Naruke T, Uno K, et al. Characteristics of advantages of positron emission tomography over computed tomography for N-staging in lung cancer patients. Jpn J Clin Oncol 2006;36:694鈥?98. CrossRef
35. Vesselle H, Pugsley JM, Vallieres E, Wood DE. The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer. J Thorac Cardiovasc Surg 2002;124:511鈥?19. CrossRef
36. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M, et al. FEG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000;41:85鈥?2.
37. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18] fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837鈥?844.
38. Ahuja V, Coleman RE, Herndon J, Patz EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer 1998;83:918鈥?24. CrossRef
39. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucosepositron emission tomography in non-small cell lung cancer: an analysis of 125 cases. J Clin Oncol 1999;17:3201鈥?206.
40. Suzuki K, Nagai K, Yoshida J, Nishimura M, Nishizaki Y. Predictors of lymph node and intrapulmonary metastasis in clinical stage IA non-small cell lung carcinoma. Ann Thorac Surg 2001;72:352鈥?56. CrossRef
41. Asamura H, Nakayama H, Kondo H, Tsuchiya R, Shimosato Y, Naruke T. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg 1996;111:1125鈥?134. CrossRef
42. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer 1995;75:2844鈥?852. CrossRef
43. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Kobayashi T, et al. Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1 N0 M0 lung adenocarcinoma. J Thorac Cardiovasc Surg 2004;128:396鈥?01. CrossRef
44. Watanabe K, Nomori H, Ohtsuka T, Naruke T, Ebihara A, Orikasa H, et al. F-18 fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinoma. Jpn J Clin Oncol 2006;36:403鈥?09. CrossRef
45. Naruke T, Goya T, Tsuchiya R, Suemasu K. The importance of surgery of non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg 1998;46:603鈥?10. CrossRef
46. Naruke T, Tsuchiya R, Kondo H, Nakayama H, Asamura H. Lymph node sampling in lung cancer: how should it be done? Eur J Cardiothorac Surg 1999;16:S17鈥揝24. CrossRef
47. Asamura H, Nakayama H, Kondo H, Tsuchiya R, Naruke T. Lobe-specific extent of systemic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastases and prognosis. J Thorac Cardiovasc Surg 1999;117:1102鈥?111. CrossRef
48. Liptay MJ, Masters GA, Winchester DJ, Edelman BL, Carrido BJ, Hirshctritt TR, et al. Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. Ann Thorac Surg 2000;70:384鈥?90. CrossRef
49. Nomori H, Horio H, Naruke T, Orikasa H, Yamazaki K, Suemasu K. Use of technetium-99m tin colloid for sentinel lymph node identification in non-small cell lung cancer. J Thorac Cardiovasc Surg 2002;124:486鈥?92. CrossRef
50. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130:151鈥?59. CrossRef
51. Sagawa M, Higashi K, Sugita M, Ueda Y, Maeda S, Toga H, et al. Fluorodeoxyglucose uptake correlates with the growth pattern of small peripheral pulmonary adenocarcinoma. Surg Today 2006;36:230鈥?34. CrossRef
52. Ohtsuka T, Nomori H, Watanabe K, Kaji M, Naruke T, Suemasu K, et al. Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathological stage I lung adenocarcinoma. Cancer 2006;107:2468鈥?473. CrossRef
53. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Cant贸 A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153鈥?58. CrossRef
54. Lee KS, Shim YM, Han J, Ahn YC, Park K, Jung KJ. Primary tumors and mediastinal lymph nodes after neoadjuvant concurrent chemoradiotherapy of lung cancer: serial CT findings with pathologic correlation. J Comput Assist Tomogr 2000;24:35鈥?0. CrossRef
55. Mateu-Navarro M, Rami-Porta R, Bastus-Piulats R, Cirera-Nogueras L, Gonzalez-Pont G. Remediastinoscopy after induction chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2000;70:391鈥?95. CrossRef
56. Van Schil P, van der Schoot J, Poniewierski J, Pauwels M, Carp L, Germonpr茅 P, et al. Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer. Lung Cancer 2002;37:281鈥?85. CrossRef
57. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study鈥擳he Leuven Lung Cancer Group. Ann Oncol 1998;9:1193鈥?198. CrossRef
58. Akhurst T, Downey RJ, Ginsberg MS, Gonen M, Bains M, Korst R, et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 2002;73:259鈥?64; discussion 264鈥?. CrossRef
59. Cerfolio RJ, Ojha B, Mukherjee S, Pask AH, Bass CS, Katholi CR. Positron emission tomography scanning with 2-fluoro-2-deoxy-d -glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 2003;125:938鈥?44. CrossRef
60. Port JL, Kent MS, Korst RJ, Keresztes R, Levin MA, Altorki NK. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2004;77:254鈥?59; discussion 259. CrossRef
61. Ohtsuka T, Nomori H, Ebihara A, Watanabe K, Kaji M, Naruke T, et al. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2006;12:89鈥?4.
62. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1017鈥?023. CrossRef - 作者单位：Hiroaki Nomori (1)
Yasuomi Ohba (1)
Kentaro Yoshimoto (1)
Hidekatsu Shibata (1)
Kenji Shiraishi (1)
Takeshi Mori (1)
1. Department of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan
文摘
Recent advances in positron emission tomography (PET) with 2-deoxy-2-fluoro [F-18]-d-glucose (FDG) has enabled not only the diagnosis and staging of lung cancer but also the prediction of its malignancy grade. However, FDG-PET has been known to have several pitfalls for imaging of lung cancer. For the effective clinical use of FDG-PET in lung cancer, we reviewed the pitfalls of using FDG-PET in the diagnosis of pulmonary nodules, semiquantitative analysis of FDG-uptake, N-staging, prediction of tumor aggressiveness, prognostic significance, and prediction of pathological response after chemoradiotherapy.